0000950170-24-107660.txt : 20240918 0000950170-24-107660.hdr.sgml : 20240918 20240918115410 ACCESSION NUMBER: 0000950170-24-107660 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240916 FILED AS OF DATE: 20240918 DATE AS OF CHANGE: 20240918 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 ORGANIZATION NAME: STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42271 FILM NUMBER: 241306547 BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER NAME: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bicara Therapeutics Inc. CENTRAL INDEX KEY: 0002023658 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-785-8308 MAIL ADDRESS: STREET 1: 245 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 ownership.xml 4 X0508 4 2024-09-16 true 0002023658 Bicara Therapeutics Inc. BCAX 0000315066 FMR LLC 245 SUMMER STREET BOSTON MA 02210 false false false true See Remark 1 false Common Stock 2024-09-16 4 C false 10818 A 10818 I F-Prime Capital Partners Life Sciences Fund VII LP Common Stock 2024-09-16 4 C false 712430 A 723248 I F-Prime Capital Partners Life Sciences Fund VII LP Common Stock 2024-09-16 4 C false 392085 A 1115333 I F-Prime Capital Partners Life Sciences Fund VII LP Series Seed Preferred Stock 2024-09-16 4 C false 10818 D Common Stock 10818 0 I F-Prime Capital Partners Life Sciences Fund VII LP Series B Preferred Stock 2024-09-16 4 C false 712430 D Common Stock 712430 0 I F-Prime Capital Partners Life Sciences Fund VII LP Series C Preferred Stock 2024-09-16 4 C false 392085 D Common Stock 392085 0 I F-Prime Capital Partners Life Sciences Fund VII LP On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VII LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 2024-09-18